BUSINESS BRIEFING / COURTS
Times Wire Reports
Amgen Inc. won an appeals court ruling that helps preserve its $5.6-billion-a-year franchise in anemia medicines from competition from Roche Holding’s Mircera drug.
An appeals court upheld part of a patent-infringement verdict won by Amgen, while ordering a new trial on other aspects. Roche can challenge the scope of an order that prevents U.S. sales of Mircera until at least 2012, the court ruled.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
